Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Company Profiles

Set Alert for Emerging Company Profiles

Kura Continues Araxes Legacy With New Menin And FTI Focuses In Cancer

Emerging Company Profile: The US biotech is advancing a pipeline of precision medicines targeting menin and farnesyltransferase for liquid and solid tumors, respectively, building on the work of two pioneering companies in the KRAS space.

Emerging Company Profile ImmunoOncology

SpyGlass To Boost Ophthalmic Drug Adherence With Intraocular Delivery Platform

Emerging Company Profile: The US biotech SpyGlass is gearing up for a Phase I/II trial in glaucoma after recently closing a $90m fundraising to help advance its intraocular delivery platform to address poor treatment adherence in chronic eye diseases.

Emerging Company Profile Financing

Evommune Looks To Advance Broad Pipeline Of Autoimmune Drugs

Emerging Company Profile: With experienced leadership and new financing, Evommune is developing a topical IRAK4 inhibitor for atopic dermatitis and earlier-stage systemic drugs for various conditions.

Financing Business Strategies

Iksuda Aims For Best-In-Class Cancer ADCs With Toolbox Approach To Technology

Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.

Emerging Company Profile ImmunoOncology

Kinaset Advances Inhaled Pan-JAK Inhibitor For Broad Use In Severe Asthma

Emerging Company Profile: The US biotech acquired its sole asset from CDMO Vectura in 2020 and is now gearing up for a Phase II proof-of-concept trial in severe asthma to help address the unmet need in non-eosinophilic patients.

Emerging Company Profile Companies

NextPoint Could Treat PD-L1 Negative Cancer Patients With HHLA2-Targeted Approach

Emerging Company Profile: Backed by strong academic talent and a recent $80m fundraising, the US biotech is on a mission to address the unmet medical need in PD-L1 negative cancer by targeting the HHLA2 pathway.

Emerging Company Profile Cancer

EvolveImmune Targets Lymphoma With Novel T-Cell Engagers Harnessing CD2

Emerging Company Profile: The firm’s use of the CD2 co-stimulant in its T cell engager design could significantly boost anti-tumor efficacy while addressing T cell exhaustion, with a first-in-human trial planned for 2024.

Emerging Company Profile ImmunoOncology

Inozyme Targets Underserved Mineralization Disorders Market With First-In-Class Enzyme Therapy

Emerging Company Profile: Fresh from a $73m follow-on offering last year, the US biotech is readying its lead asset for a pivotal trial in ultra-rare but debilitating mineralization disorders that affect infants and children.

Emerging Company Profile Rare Diseases

ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach

Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.

Emerging Company Profile Companies

Ratio To Fine-Tune Radioligand Approach In Cancer With Trillium And Macropa Platforms

Emerging Company Profile: The US biotech’s Trillium platform, which has caught the eye of Bayer, could enhance radioligand pharmacokinetics and bioavailability while reducing side effects, enabling the development of both therapeutics and imaging compounds.

Emerging Company Profile Cancer

Cingulate Sets Sights On $18bn ADHD Market With Precision Timed-Release Approach

Emerging Company Profile: The US firm’s lead candidate contains a gold standard ADHD simulant packaged in a compressed tablet that releases the ingredient at timed intervals to address symptoms for up to 16 hours.

Emerging Company Profile Platform Technologies

Ellipses Accelerates Cancer Treatment R&D With ‘Unique’ Business Model

Emerging Company Profile: The UK biotech is working to expedite its portfolio of acquired drug candidates for cancer through the clinic before out-licensing to big pharma in a bid to bring patients the treatments they need sooner rather than later.

Emerging Company Profile Cancer

SFA Therapeutics Harnesses Power Of Bacterial Metabolites To Treat Inflammatory Disease

Emerging Company Profile: The US biotech is advancing its lead candidate into a Phase Ib psoriasis trial as it works to validate its bacterial metabolite-based drug platform, which exemplifies a new generation of microbiome technology.

Emerging Company Profile Companies

Medannex Advances First ANAX1 Antagonist With Modular Cancer Trial Approach

Emerging Company Profile: The Scottish biotech is the only firm targeting the ANAX1 protein with plans to initiate a modular Phase I trial that could look at multiple tumor types before expanding to the autoimmune space.

Emerging Company Profile Companies

Tetraneuron Touts Its Multifactorial Gene Therapy Solution For Alzheimer’s

Emerging Company Profile: The biotech plans to enter the clinic next year with a gene therapy targeting the E2F4 protein in the hopes of halting Alzheimer’s disease progression and restoring lost function.

Emerging Company Profile Neurology
See All
UsernamePublicRestriction

Register